{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:32:23Z","timestamp":1781724743766,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.ygyno.2013.10.031","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T01:30:17Z","timestamp":1383528617000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer"],"prefix":"10.1016","volume":"132","clinical-trial-number":[{"clinical-trial-number":"nct00545792","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Akila N.","family":"Viswanathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Feltmate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Sadow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.10.031_bb0005","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0010","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/1097-0142(19940815)74:4<1303::AID-CNCR2820740420>3.0.CO;2-G","article-title":"Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer","volume":"74","author":"Sears","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0015","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ygyno.2004.11.008","article-title":"Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer","volume":"96","author":"Albuquerque","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0020","first-page":"193","article-title":"Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer","volume":"51","author":"Mazurek","year":"2004","journal-title":"Neoplasma"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1046\/j.1525-1438.2001.011002164.x","article-title":"Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement","volume":"11","author":"Gornall","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0030","first-page":"242","article-title":"Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer","volume":"53","author":"Mazurek","year":"2006","journal-title":"Neoplasma"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0035","first-page":"3374","article-title":"Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation","volume":"59","author":"Gorski","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0040","first-page":"5565","article-title":"Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions","volume":"60","author":"Lee","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0045","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1158\/0008-5472.CAN-06-1010","article-title":"Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor","volume":"66","author":"Bao","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.radonc.2006.03.021","article-title":"The influence of fractionated radiation therapy on plasma vascular endothelial growth factor (VEGF) concentration in dogs with spontaneous tumors and its impact on outcome","volume":"79","author":"Wergin","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0060","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2011.10.060","article-title":"A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417","volume":"83","author":"Schefter","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0065","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0070","first-page":"3525","article-title":"Bevacizumab therapy in patients with recurrent uterine neoplasms","volume":"27","author":"Wright","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0075","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2012.08.001","article-title":"Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?","volume":"127","author":"McCann","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0080","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ijrobp.2007.09.042","article-title":"Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer","volume":"71","author":"Small","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ygyno.2013.10.031_bb9000","first-page":"1262","article-title":"Int J Radiat Oncol Biol Phys","volume":"85","author":"Poorvu","year":"2013","journal-title":"Duodenal and Other Gastrointestinal Toxicity in Cervical and Endometrial Cancer Treated With Extended-Field Intensity Modulated Radiation Therapy to Paraaortic Lymph Nodes"},{"key":"10.1016\/j.ygyno.2013.10.031_bb9005","first-page":"1","article-title":"Radiation dose escalation using intensity modulated radiation therapy for gross unresected node-positive endometrial cancer","volume":"1","author":"Townamchai","year":"2013","journal-title":"Pract Radiat Oncol Epub"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-8258(03)00126-4","article-title":"Survival after relapse in patients with endometrial cancer: results from a randomized trial","volume":"89","author":"Creutzberg","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0090","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0360-3016(03)00414-0","article-title":"Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy","volume":"56","author":"Jhingran","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.10.031_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2013.08.040","article-title":"Clinical outcomes following 3D image-guided brachytherapy for vaginal recurrence of endometrial cancer","author":"Lee","year":"2013","journal-title":"Gynecol Oncol Epub"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813012808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813012808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T22:50:41Z","timestamp":1539211841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813012808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0090825813012808"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.10.031","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718169709.793527260","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}